Sign in

You're signed outSign in or to get full access.

Rohit Bhasin

Rohit Bhasin

Research Analyst at Morgan Stanley

New York, NY, US

Rohit Bhasin is an Equity Research Associate at Morgan Stanley & Co. LLC, specializing in coverage of health and consumer services companies, including names such as Fractyl Health Inc. and Mirum Pharmaceuticals. Since joining Morgan Stanley in August 2023, Bhasin has been actively involved in earnings call analysis and company research, contributing to insightful investment discussions and supporting major institutional clients. Previously, he held research roles at Needham & Co. LLC and led pharmacy operations at AgeWell New York LLC, reflecting a strong background in both finance and healthcare. Dr. Bhasin holds a doctorate from St. John's University, an MBA from Baruch College, and is registered through FINRA, underscoring his robust professional credentials.

Rohit Bhasin's questions to Viking Therapeutics (VKTX) leadership

Question · Q3 2025

Rohit Bhasin asked about expectations for OpEx spend moving forward, specifically if R&D would continue to increase. He also asked if there are still plans to partner VK2809 given recent interest in the MASH space.

Answer

Greg Zante (CFO, Viking Therapeutics) stated that OpEx is up due to Phase 3 activities and expects this pace to continue. Brian Lian (President and CEO, Viking Therapeutics) confirmed an uptick in interest for the MASH asset (VK2809) due to renewed focus and recognition of value in the MASH space, similar to M&A in obesity.

Ask follow-up questions

Fintool

Fintool can predict Viking Therapeutics logo VKTX's earnings beat/miss a week before the call

Question · Q3 2025

Rohit Bhasin asked about expectations for OpEx spend moving forward, specifically if R&D would continue to increase, and if there are still plans to partner VK2809 given recent interest in the MASH space.

Answer

Greg Zante (CFO, Viking Therapeutics) confirmed that OpEx, particularly R&D, is expected to continue at higher levels due to phase three activities. Brian Lian (President and CEO, Viking Therapeutics) acknowledged increased investor and partner interest in the MASH space, confirming an uptick in interest for the VK2809 asset.

Ask follow-up questions

Fintool

Fintool can write a report on Viking Therapeutics logo VKTX's next earnings in your company's style and formatting

Rohit Bhasin's questions to FRACTYL HEALTH (GUTS) leadership

Question · Q2 2025

Rohit Bhasin, on behalf of Mike Ulz at Morgan Stanley, asked about new learnings from the evolving GLP-1 market and the potential impact on the outlook for Revita and Rejuva.

Answer

Harith Rajagopalan, Co-Founder, CEO & Director, highlighted two key trends: patients are now frequently asking when they can stop GLP-1 medications, and real-world data is showing lower effectiveness for these drugs than seen in clinical trials. He explained that these trends underscore the significant unmet need for a durable, disease-modifying therapy like Revita.

Ask follow-up questions

Fintool

Fintool can predict FRACTYL HEALTH logo GUTS's earnings beat/miss a week before the call

Rohit Bhasin's questions to Mirum Pharmaceuticals (MIRM) leadership

Question · Q4 2024

Rohit Bhasin, on for Mike Ulz, asked about the LIVMARLI patient mix between Alagille syndrome and PFIC in Q4, its expected evolution in 2025, and the status of expanded access PFIC patients.

Answer

CEO Chris Peetz confirmed that all U.S. expanded access PFIC patients were converted to commercial product by Q3 2024. He noted that while Alagille syndrome patients are the majority, PFIC patient starts have significantly increased since Q3, becoming a substantial contributor to new patient growth.

Ask follow-up questions

Fintool

Fintool can predict Mirum Pharmaceuticals logo MIRM's earnings beat/miss a week before the call